Drug Combination Details
| General Information of the Combination (ID: C46171) | |||||
|---|---|---|---|---|---|
| Name | Honokiol NP Info | + | Rapamycin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Renal cell carcinoma
[ICD-11: 2C90]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | PD-L1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | ||
| ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer. | |||||
